Description: Taj Pharmaceuticals Ltd is well recognized Manufacturer, Exporter and Supplier of Hydroxycarbamide Tablets from Vapi, Gujarat India. Routine monitoring is important to check your blood counts and ensure the medicine is working safely. Make sure to attend regular blood test appointments. Taj Pharmaceuticals Ltd is a leading Hydroxycarbamide (Hydroxyurea) Tablets manufacturer, exporter, and supplier in India, recognized for its premium brand THAROLAX Tablets. Produced at the company’s WHO-GMP certified facility in Vapi, Gujarat, these tablets are trusted worldwide for their high quality, purity, and therapeutic effectiveness. Hydroxycarbamide Tablets are widely prescribed for the treatment of head and neck cancer, chronic myeloid leukemia (CML), and sickle cell disease. The medicine works by inhibiting DNA synthesis in rapidly dividing cancer cells and by increasing fetal hemoglobin (HbF) levels in patients with sickle cell anemia, helping improve red blood cell function and reduce complications. With strong global reach across India, Africa, the Middle East, and Latin America, Taj Pharma is committed to delivering affordable, reliable, and safe healthcare solutions. The company’s advanced R&D facilities, international certifications including ISO 9001:2015, and stringent quality assurance practices ensure products that meet global regulatory standards. As a trusted PCD Pharma Franchise provider and global supplier, Taj Pharmaceuticals continues to lead in innovation and accessibility. Taj Pharmaceuticals Ltd – your dependable source for Hydroxycarbamide (Hydroxyurea) Tablets, offering excellence in manufacturing, quality, and patient care worldwide. Taj Pharma India is well known Manufacturer, Exporter and Supplier of Hydroxycarbamide (Hydroxyurea) Tablets from Vapi, Gujarat India. In cancer, Hydroxyurea inhibits the enzyme ribonucleotide reductase, which plays a critical role in the synthesis of DNA by converting ribonucleotides into deoxyribonucleotides. This inhibition disrupts DNA synthesis, particularly in rapidly dividing cancer cells, resulting in cell cycle arrest and reduced tumor proliferation. In sickle cell disease, hydroxyurea increases the production of fetal hemoglobin (HbF) in red blood cells. Higher levels of HbF reduce the formation of sickled cells, improve red blood cell flexibility, enhance blood flow, and decrease the frequency of painful vaso-occlusive episodes and related complications.
Dimensions: 2560 x 1707
File Type: jpeg
File Size: 230 KB
